Thursday, December 3, 2020
Home Latest Pharma-News USFDA Approved GIVLAARI(givosiran) for the Treatment of Adults with Acute Hepatic...

USFDA Approved GIVLAARI(givosiran) for the Treatment of Adults with Acute Hepatic Porphyria

Nov. 20, 2019: Alnylam Pharmaceuticals, the leading RNAi therapeutics company, announced  the USFDA approved GIVLAARI (givosiran) injection (subcutaneous) for the treatment of adults with acute hepatic porphyria (AHP).

AHP is an exceptional, genetic diseases characterized by devitalizing, potentially life-threatening attacks and, for some patients, chronic manifestations that depressingly impact daily performance and quality of life.

- Advertisement -

Long-standing complications of AHP are chronic neuropathic pain, chronic kidney disease, hypertension and liver disease. GIVLAARI reduces the rate of porphyria attacks that required hospitalizations, urgent healthcare visits or IV hemin administration at home. http://investors.alnylam.com/news-releases/news-release-details/alnylam-announces-approval-givlaaritm-givosiran-us-food-and-drug

LEAVE A REPLY

Please enter your comment!
Please enter your name here

one + five =

Most Popular

FDA approves Xolair® (omalizumab) for adults with nasal polyps

December 01, 2020: "Roche announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA)...

UK authorises Pfizer/BioNTech COVID-19 vaccine

December 02, 2020: "A Department of Health and Social Care spokesperson said: The government has accepted the recommendation from...

WHO Releases COVID-19 App for Trusted and Timely Updates

 December 01, 2020: The WHO has published a new mobile app to centralize the most trusted updates about COVID-19, and to guide...